Details of the Drug

General Information of Drug (ID: DM5S7IG)

Drug Name

Irbesartan

Synonyms

Aprovel; Avapro; Karvea; SR-47436; BMS-186295; BMS 186295; SR 47436; UNII-J0E2756Z7N; CHEMBL1513; YOSHYTLCDANDAN-UHFFFAOYSA-N; J0E2756Z7N; NCGC00095122-01; AK-57149; DSSTox_CID_3169; Irbesartan [USAN:INN]

Indication

Disease Entry	ICD 11	Status	REF
Hypertension	BA00-BA04	Approved	[1]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Investigative	[2], [3]

Therapeutic Class

Antiviral Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

428.5

Topological Polar Surface Area (xlogp)

4.1

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption Tmax: The time to maximum plasma concentration (Tmax) is 1.5-2 h [4]
Bioavailability: The bioavailability of drug is 60-80% [4]
Clearance: The renal clearance of drug is 3.0-3.5 mL/min [5]
Elimination: 20% of a radiolabelled oral dose is recovered in urine, and the rest is recovered in the feces, only less than 2% of the dose is recovered in urine as the unchanged drug [6]
Half-life: The concentration or amount of drug in body reduced by one-half in 11 - 15 hours [5]
Metabolism: The drug is metabolized via the glucuronidation and oxidation in the liver [7]
Vd: The volume of distribution (Vd) of drug is 53-93 L [5]

Chemical Identifiers

Formula: C25H28N6O
IUPAC Name: 2-butyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one
Canonical SMILES: CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5
InChI: InChI=1S/C25H28N6O/c1-2-3-10-22-26-25(15-6-7-16-25)24(32)31(22)17-18-11-13-19(14-12-18)20-8-4-5-9-21(20)23-27-29-30-28-23/h4-5,8-9,11-14H,2-3,6-7,10,15-17H2,1H3,(H,27,28,29,30)
InChIKey: YOSHYTLCDANDAN-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 3749
ChEBI ID: CHEBI:5959
CAS Number: 138402-11-6
DrugBank ID: DB01029
TTD ID: D0AL2K
ACDINA ID: D00330

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
HUMAN type-1 angiotensin II receptor (AGTR1)	TTPKMXQ	AGTR1_HUMAN	Antagonist	[3], [2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 203534.
2	Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001 Sep 20;345(12):851-60. Clinical Trial;
3	Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res. 2020 Mar 4.
4	Marino MR, Langenbacher K, Ford NF, Uderman HD: Pharmacokinetics and pharmacodynamics of irbesartan in healthy subjects. J Clin Pharmacol. 1998 Mar;38(3):246-55.
5	FDA Approved Drug Products: Irbesartan Oral Tablets
6	Sandoz Canada: Irbesartan Product Monograph
7	Vickers AE, Sinclair JR, Zollinger M, Heitz F, Glanzel U, Johanson L, Fischer V: Multiple cytochrome P-450s involved in the metabolism of terbinafine suggest a limited potential for drug-drug interactions. Drug Metab Dispos. 1999 Sep;27(9):1029-38.
8	Controversies of renin-angiotensin system inhibition during the COVID-19 pandemic. Nat Rev Nephrol. 2020 Apr 3.